Discover the Science of Health
Key cells in the brain region known as the hippocampus are formed in the base of the brain late in fetal life and undertake a long journey before reaching their final destination in the center of the brain shortly after birth, according to researchers at the National Institutes of Health (NIH).
Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
A summary of talks from day 1 of the Institute for Systems Biology (ISB) 2011 Systems Biology and P4 Medicine symposium.
A summary of talks from day 2 of the Institute for Systems Biology (ISB) 2011 Systems Biology and P4 Medicine symposium.
The Alzheimer’s Disease Genetics Consortium (ADGC) led by the University of Pennsylvania School of Medicine, the University of Miami, and the Boston University School of Medicine, recently identified five new genes linked to late-onset Alzheimer’s disease.
Researchers have found that a combination biomarker approach improves risk prediction for chronic kidney disease (CKD).
New England Peptide recently announced that it and twelve other product and service companies have started the global Proteomics Innovation Network to collaborate on unmet needs in drug discovery and personalized medicine.
Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at BiomarkerCommons.org. Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.
A roundup of five research studies on cancer biomarkers that were presented earlier this week at the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida.
In the February edition of the journal Pharmacogenomics (Future Medicine), Greg Gibson from the School of Biology at the Georgia Institute of Technology provides a summary of talks and discussion from the Inaugural Australian Biomarker Discovery Conference (BDC 2010) held in Shoal Bay, Australia in December.
According to a recent study published in the Journal of the American Medical Association, plasma clusterin levels are significantly associated with prevalence and severity of Alzheimer’s disease (AD), but not with incidence.
Sage Bionetworks has started projects to build advanced computational models of neurobiological disease through two ongoing partnerships with the CHDI Foundation and Takeda Pharmaceuticals.
Late last month, NeoProteomics, a bioinformatics spinoff company from Case Western Reserve University, signed an exclusive option agreement to license technology from the university.
Jennifer Raymond, an associate professor in neurobiology at Stanford University, is building a circuit diagram of the brain. By bridging the gap between individual synapses and whole brain learning and memory, her research is offering new insights and strategies for medical rehabilitation and education.
Neuroimaging is one of the most promising research areas for detection of the earliest stages of Alzheimer’s disease. Using neuroimaging together with proteomics, researchers report in the Journal of Alzheimer’s Disease that a blood test may reflect the levels of beta amyloid protein in the brain — a hallmark of the disease [1]. The findings may eventually lead to a blood test that helps to predict the risk for developing Alzheimer’s disease.
